Compare Gilead Sciences, Inc. (GILD) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Open Text Corporation — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Open Text Corporation trades at $23.98 (market cap $5.98B). The key difference: Gilead Sciences, Inc. is far larger — about 27.6× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.53%). Which is the better fit depends on your goals.
| GILD | OTEX | |
|---|---|---|
Market Cap | $164.99B | $5.98B |
Sector | Health | Technology |
52-Week High | $155.80 | $39.69 |
52-Week Low | $110.56 | $20.01 |
Enterprise Value | $188.06B | $11.00B |
Dividend Yield | 2.47% | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Open Text Corporation (OTEX) trades at $24.94, down 2.81% in the last session, with a bullish technical signal from moving averages and strong support at $24. The company reported Q2 2026 EPS of $1.23, beating estimates, and maintains robust profitability with a 73.74% gross margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe, signaling strategic expansion.
OTEX presents a value opportunity with a low P/E of 9.58 and a consensus price target of $29.33, implying 17.6% upside. Risks include high long-term debt of $6.34 billion and competitive pressures in software. Analyst sentiment is mixed, with 42% buy ratings, but earnings beats and dividend stability support a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
